Latest news from Araclon Biotech on Newswise en-us Copyright 2024 Newswise 115 31 / /images/newswise-logo-rss.gif /articles/the-results-of-phase-i-clinical-trial-of-the-araclon-biotech-alzheimers-vaccine-support-its-continuation/?sc=rsin /articles/the-results-of-phase-i-clinical-trial-of-the-araclon-biotech-alzheimers-vaccine-support-its-continuation/?sc=rsin Mon, 01 Aug 2016 08:05:05 EST /PRNewswire/ -- Araclon Biotech, in which Grifols is the majority shareholder, has presented the results of the phase I clinical trial for its active immunotherapy against Alzheimer's disease (ABvac40) at the Alzheimer's Association International Conference (AAIC 2016), held in Toronto (Canada) from July 24 to 28, and organized by the American Alzheimer's Association. Araclon Biotech